Table 3.

Overview of the validation cohort with ALK-IHC, FISH, and tumor responses to crizotinib in 16 patients with stage IV NSCLC from 4 hospitals treated with crizotinib

PatientALK-IHCFISHResponsePFS, moOS, mo
EV1+PD3.93.9
EV2++PR10.345.6
EV3++PR4.49.2
EV4++CR19.720.1
EV5++SD4.98.2
EV6++PR10.617.5
EV7++PR6.19.2
EV8++SD1.95.1
EV9++PR1.41.4
EV10+PD1.83.7
EV11++SD10.610.6
EV12++PR13.815.6
EV13+PD4.07.6
EV14++PR6.28.7
EV15+PD1.01.7
EV16+PD1.618.1
  • NOTE: Dichotomous ALK-IHC is called either positive or negative. ALK-FISH is positive if >15% of 100 counted neoplastic nuclei show the defined break-apart pattern.

  • Abbreviations: CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.